Sugi Predict

Sugi Predict / Compounds / SCHEMBL715607

SCHEMBL715607

SCHEMBL715607

CC(=O)N1CCN(c2nc3c(Cl)cccc3cc2C(C)NC(=O)O)CC1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 4/20 0.43
▸ PIK3CD O00329 2/20 0.41
▸ P2RY12 Q9H244 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CNR1 P21554 2/20 0.39
▸ NCF1 P14598 2/20 0.39
▸ NPY5R Q15761 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ P2RX3 P56373 1/20 0.37
▸ SMO Q99835 2/20 0.37
▸ PDE4A P27815 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ PDE4C Q08493 1/20 0.37
▸ PDE4D Q08499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716672 0.90 PIK3CD (0.51) CNR2PIK3CDMAPTTP53NCF1
SCHEMBL716164 0.89 AKT1 (0.40) CNR2PIK3CD
SCHEMBL716682 0.89 MAPT (0.48) CNR2P2RY12MAPTTP53CNR1
SCHEMBL717045 0.87 PIK3CB (0.40) PIK3CDKDM4EALDH1A1
SCHEMBL716476 0.86 CNR1 (0.40) CNR2CNR1NPY5RKDM4EALDH1A1
SCHEMBL713901 0.86 AKT1 (0.43) CNR2P2RY12CNR1KDM4EALDH1A1
SCHEMBL715574 0.84 STK4 (0.41) CNR2CNR1ALDH1A1SMO
SCHEMBL714860 0.83 PIK3CD (0.42) CNR2PIK3CDP2RY12MAPTTP53
SCHEMBL714861 0.83 PIK3CD (0.42) CNR2PIK3CDP2RY12MAPTTP53
SCHEMBL714176 0.83 P2RX7 (0.38) PIK3CDP2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 — — EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 — — US disclosed
US-8653105-B2 Quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2014-02-18 — — US disclosed
US-20130012517-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2013-01-10 — — US disclosed
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-04-19 — — US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 CNR2 1488/4885PIK3CD 12/4885P2RY12 914/4885
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors PI4KA, PDPK1, PIK3CA CNR2 1676/4885PIK3CD 6/4885P2RY12 460/4885
US-20130012517-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors PDXK, MAP2K2, PDPK1 CNR2 754/4885PIK3CD 13/4885P2RY12 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.